Climb Bio (NASDAQ: CLYM) net income
Climb Bio reported a net loss of $59.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $73.9m. Earnings per share were −$0.88.
Climb Bio's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$59.9m | — | — | −$0.88 |
| 2024 | −$73.9m | — | −908.7% | −$1.53 |
| 2023 | −$35.1m | — | −760.2% | −$1.30 |
| 2022 | −$45.2m | — | — | −$1.72 |
| 2021 | −$47.5m | — | — | −$4.24 |
| 2020 | −$20.7m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Climb Bio net income compared with its sector
By net income for its latest fiscal year, Climb Bio ranks 275th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 273rd | Adaptive Biotechnologies | −$59.5m | −21.5% |
| 274th | Onkure Therapeutics | −$59.5m | −1,729.6% |
| 275th | Climb Bio | −$59.9m | — |
| 276th | Contineum Therapeutics | −$60.0m | — |
| 277th | Fulgent Genetics | −$60.5m | −18.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Climb Bio
- How much did Climb Bio earn in fiscal 2025?
- Climb Bio reported a net loss of $59.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $73.9m.
- What are the earnings per share of Climb Bio?
- They were −$0.88 in fiscal 2025, compared with −$1.53 in fiscal 2024.
- Where does Climb Bio rank in its sector by net income?
- It ranks 275th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Climb Bio come from?
- From the annual report (Form 10-K) that Climb Bio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Climb Bio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Climb Bio: the Climb Bio page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.